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INTRODUCTION
Heart failure is a chronic disease associated 
with significant mortality and poor 
quality of life.1–3 Patients may present to 
primary care with symptoms of gradual-
onset breathlessness, fatigue, and ankle 
swelling.4 These symptoms are not unique 
to heart failure and can be associated with 
other conditions.5–7 Making an accurate and 
timely diagnosis is crucial, and requires 
referral for objective testing, but deciding 
who to refer can be challenging.8–10 
Clinical decision rules (CDRs) can help 
clinicians to assess the probability that a 
patient has a particular condition.11 They are 
used widely in medicine to inform decisions 
about investigation and management.12,13 
Mant and colleagues developed a CDR for 
heart failure by undertaking a systematic 
review that identified 11 prospective studies 
set in primary care.14 The decision rule was 
derived from an individual patient dataset 
from one of these studies (Zaphiriou et al )15 
and externally validated on four others that 
included relevant variables.16–19 
The CDR included three clinical elements, 
as shown in Box 1, and was combined with 
N-Terminal pro-B type natriuretic peptide 
levels (NT-proBNP) to identify those likely 
to have heart failure and therefore requiring 
referral for further diagnostic testing. 
Natriuretic peptides are routinely used 
in the diagnosis of heart failure, although 
doubt remains about the most appropriate 
cut-off levels required to optimise diagnostic 
accuracy.20 The European Society of 
Cardiology (ESC) advocates an NT-proBNP 
threshold of 125 pg/ml,8 below which 
heart failure can be ruled out, whereas 
the National Institute for Health and Care 
Excellence (NICE) in England (where the 
study took place) recommends a much 
higher NT-proBNP threshold of 400 pg/ml.4 
The aim of this diagnostic accuracy study 
was to assess the performance of the CDR, 
CDR+NT-proBNP, or NT-proBNP alone 
in identifying patients with heart failure 
presenting to primary care.
METHOD
The full methods for the REFER study have 
been previously published elsewhere.21
Research
Abstract
Background
Symptoms of breathlessness, fatigue, and 
ankle swelling are common in general practice 
but deciding which patients are likely to have 
heart failure is challenging.
Aim
To evaluate the performance of a clinical 
decision rule (CDR), with or without N-Terminal 
pro-B type natriuretic peptide (NT-proBNP) 
assay, for identifying heart failure.
Design and setting
Prospective, observational, diagnostic validation 
study of patients aged >55 years, presenting 
with shortness of breath, lethargy, or ankle 
oedema, from 28 general practices in England. 
Method
The outcome was test performance of the CDR 
and natriuretic peptide test in determining 
a diagnosis of heart failure. The reference 
standard was an expert consensus panel of 
three cardiologists. 
Results
Three hundred and four participants were 
recruited, with 104 (34.2%; 95% confidence 
interval [CI] = 28.9 to 39.8) having a confirmed 
diagnosis of heart failure. The CDR+NT-proBNP 
had a sensitivity of 90.4% (95% CI = 83.0 to 95.3) 
and specificity 45.5% (95% CI = 38.5 to 52.7). 
NT-proBNP level alone with a cut-off <400 pg/
ml had sensitivity 76.9% (95% CI = 67.6 to 84.6) 
and specificity 91.5% (95% CI = 86.7 to 95.0). At 
the lower cut-off of NT-proBNP <125 pg/ml, 
sensitivity was 94.2% (95% CI = 87.9 to 97.9) and 
specificity 49.0% (95% CI = 41.9 to 56.1).
Conclusion
At the low threshold of NT-proBNP <125 pg/ml, 
natriuretic peptide testing alone was better than 
a validated CDR+NT-proBNP in determining 
which patients presenting with symptoms went 
on to have a diagnosis of heart failure. The 
higher NT-proBNP threshold of 400 pg/ml may 
mean more than one in five patients with heart 
failure are not appropriately referred. Guideline 
natriuretic peptide thresholds may need to be 
revised. 
Keywords
clinical decision rule; diagnostic; 
echocardiography; general practice; heart 
failure; natriuretic peptide.
CJ Taylor, MA, MPH, PhD, FRCGP, GP and NIHR 
academic clinical lecturer; FDR Hobbs, FRCP, 
FESC, FRCGP, FMedSci, professor of primary 
care, Nuffield Department of Primary Care 
Health Sciences, University of Oxford, Oxford. 
AK Roalfe, MSc, head of statistics; R Iles, MSc, 
research fellow; P Barton, MA, PhD, reader in 
mathematical modelling; J Deeks, PhD, CStat, 
professor of biostatistics; D McCahon, PhD, 
lecturer in primary care, Institute of Applied 
Health Research, University of Birmingham, 
Birmingham. MR Cowie, MD, MSc, FRCP, FRCP 
(Ed), FESC, professor of cardiology; G Sutton, MD, 
FRCP, consultant cardiologist (retired), Faculty 
of Medicine, National Heart and Lung Institute, 
Imperial College London. RC Davis, MD, FRCP, 
consultant cardiologist, Department of Cardiology, 
Sandwell and West Birmingham Hospitals, 
Lyndon, West Bromwich. J Mant, MA, MD, FRCP 
(Ed), FFPH, professor of primary care research, 
Department of Public Health and Primary 
Care, University of Cambridge, Cambridge. 
T McDonagh, MD, FRCP, FESC, professor of 
heart failure, Department of Cardiology, King’s 
College Hospital, London. L Tait, PhD, CSci, 
senior research fellow, School of Health Sciences, 
Nottingham.
Address for correspondence
FD Richard Hobbs, University of Oxford, Nuffield 
Department of Primary Care Health Sciences, 
Radcliffe Primary Care Building, Radcliffe 
Observatory Quarter, Woodstock Road, Oxford 
OX2 6GG, UK.
E-mail: richard.hobbs@phc.ox.ac.uk.
Submitted: 25 July 2016; Editor’s response: 
26 August 2016; final acceptance: 21 September 
2016.
©British Journal of General Practice
This is the full-length article (published online 
6 Dec 2016) of an abridged version published in 
print. Cite this version as: Br J Gen Pract 2017; 
DOI: https://doi.org/10.3399/bjgp16X688393
Clare J Taylor, Andrea K Roalfe, Rachel Iles, FD Richard Hobbs and the REFER investigators
Primary care REFerral for EchocaRdiogram 
(REFER) in heart failure:
a diagnostic accuracy study
e94  British Journal of General Practice, February 2017
Study design and participants
The REFER study was a prospective, 
observational, diagnostic validation design 
to assess the performance of the Male, 
Infarction, Crepitations, Edema (MICE) rule 
and NT-proBNP level in identifying patients 
with heart failure. The study population 
was primary care patients aged >55 years 
presenting with recent new-onset 
shortness of breath, lethargy, or peripheral 
ankle oedema of >48 hours’ duration for 
which there was no other obvious cause. 
Patients were excluded if they were unable 
to give consent, had a previous confirmed 
diagnosis (that is, with objective evidence) 
of heart failure, an obvious alternative 
diagnosis, severe symptoms requiring 
immediate management, or recent (within 
60 days) acute coronary syndrome.
Recruitment
The original study protocol stated a 
recruitment target of 500 participants from 
20 practices (equivalent to 25 participants 
per practice) over an 18-month period. Due 
to difficulties in prospectively recruiting 
patients within GP appointments at a time 
of unprecedented demand on the service, 
the length of the recruitment period was 
extended and the number of practices 
increased. 
The recruitment phase of the REFER study 
started on 1 May 2011 and completed on 31 
August 2013. Participants were recruited 
from a random sample of 28 general 
practices in central England, stratified by 
practice list size and deprivation quartile.22 
Participating practices were asked to 
invite all presenting patients who met 
the inclusion criteria to join the study 
consecutively. Assessment was undertaken 
at the research clinic within 7 days of 
participants presenting to their GP.
Assessment clinics
Assessments were carried out within 7 days 
of recruitment by trained research nurses 
and an echocardiographer accredited by the 
British Society of Echocardiography (BSE). 
Informed consent was obtained, and then 
detailed clinical history and examination, 
blood testing, electrocardiograph (ECG), 
and echocardiogram were carried out. Two 
attempts at blood taking were allowed. The 
NT-proBNP level was determined using a 
point-of-care device (Roche Diagnostics, 
UK).
Reference standard
The reference standard was an expert 
consensus panel of three cardiology 
specialists, who reviewed each case 
blinded to the assessments by other panel 
members. The ESC 2012 guideline was 
used to define heart failure.8 To assess 
incorporation bias, the panel was presented 
with clinical information and investigation 
results in three separate stages. At Step 1, 
clinical assessment (excluding the CDR 
variables), ECG, and echo findings were 
presented. At Step 2, the CDR components 
(male, history of myocardial infarction, 
crepitations, and oedema) were added and 
finally, at Step 3, the NT-proBNP result was 
included. The cardiology specialists were 
asked to record if the patient did or did not 
have heart failure at each of the three steps.
Statistical methods
A sample of 500 symptomatic patients 
attending their GP with breathlessness, 
lethargy, or ankle swelling was proposed. 
This sample size was sufficient to estimate 
the sensitivity of the CDR to within 4% 
and specificity to within 6% at the 95% 
confidence level. Calculations were based 
on a sensitivity of 94% and specificity of 
48% obtained from the previous individual 
patient data meta-analysis19 and prevalence 
of heart failure in a symptomatic population 
of 30%.
How this fits in
Patients with symptoms suggestive of 
heart failure often present to primary care. 
The diagnosis requires objective evidence 
of cardiac dysfunction, usually found using 
echocardiography, but deciding which 
patients to refer for further testing is 
challenging. This study found a validated 
clinical decision rule (CDR) added little to 
diagnostic accuracy and that N-Terminal 
pro-B type natriuretic peptide levels 
(NT-proBNP) testing alone should be 
carried out in symptomatic patients with 
suspected heart failure. The cut-off needs 
to be low enough to ensure cases are not 
missed.
Box 1. The ‘MICE’ clinical decision rule
Refer straight for echocardiography if the patient has any one of:
• a history of myocardial Infarction;
•  basal Crepitations; or
•  ankle oEdema in a Male.
Otherwise, carry out an NT-proBNP test and refer straight for echocardiography if level is above one of 
three cut-offs set by sex/symptoms recorded in the clinical rule: 
• female without ankle oedema, refer if NT-proBNP >620–1060 pg/ml; 
• male without ankle oedema, refer if NT-proBNP >390–660 pg/ml; or 
• female with ankle oedema, refer if NT-proBNP >190–520 pg/ml.
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Participants with and without a diagnosis 
of heart failure at Step 3 were compared 
using independent t-tests or Wilcoxon 
ranked sum tests for continuous measures 
and χ2 tests for categorical variables. 
The main outcome measures were test 
performance of the CDR and natriuretic 
peptide test — alone and in combination — 
in estimating a diagnosis of heart failure. 
The findings of the expert consensus panel 
determined if heart failure — the Observed 
Disease — was present or absent. The CDR 
and NT-proBNP results were also used 
to determine whether heart failure was 
likely to be present — the Test Disease — 
and referral for echocardiography would 
have been indicated. Observed versus Test 
Disease status was then cross-tabulated 
to determine the sensitivity and specificity, 
positive predictive value (PPV), and negative 
predictive value (NPV) for the CDR, 
NT-proBNP, and their combination; and 
also by NT-proBNP cut-offs of 125 pg/ ml 
and 400 pg/ml suggested by the ESC and 
NICE guidelines respectively.4,8 
The binomial exact method was used to 
calculate 95% confidence intervals (CIs). 
Receiver operating characteristics (ROC) 
curves were generated to determine the 
overall discriminatory ability of each test 
in predicting a diagnosis of heart failure. 
Comparisons were made between 
performance characteristics of the current 
cohort and those observed in the original 
derivation dataset.15 The original data 
used in the analysis are available from the 
authors.
RESULTS
Participants
Figure 1 shows a flow diagram for 
recruitment. Three hundred and ninety-
seven patients were eligible for inclusion; 
45 were excluded. Of the 352 participants 
recruited, 48 did not have a blood test (due 
to failed venepuncture) so were excluded 
from the final analysis. The remaining 304 
participants formed the validation cohort; 
participants were similar to those excluded, 
with respect to demography and medical 
history, except previous record of heart 
failure, where those without NT-proBNP 
had a higher prevalence (2.3% versus 
8.3%). These heart failure labels from the 
routine clinical records were, however, 
not necessarily confirmed with objective 
evidence or a formal diagnosis. 
The clinical and demographic 
characteristics of the study population 
are shown in Table 1. The mean age was 
73.9 years (standard deviation [SD] 8.8) and 
180 (59.2%) participants were female. The 
cohort had a range of ethnic mix including 
18.4% Asian or Asian British. Over half 
of participants had all three symptoms 
of breathlessness, ankle oedema, and 
Eligible patients n = 397
Study participants 
n = 352 
(28 general practices)
Step 1 
n = 352
Step 2 
n = 352
Step 3 
n = 304
No NT-proBNP 
n = 48 
Excluded n = 45 
Reasons:
 Did not consent n = 37
 DNA n = 3
 Lost contact n = 4
 Hospitalised n = 1
Figure 1. Flow diagram to show number of 
participants in REFER study. Step 1 = clinical 
info  +ECG+echo. Step 2 = CDR variables. Step 
3 = NT–proBNP result. CDR = clinical decision rule. 
DNA = did not attend. NT-proBNP = N-Terminal pro-B 
type natriuretic peptide levels.
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lethargy. Cardiovascular risk factors such as 
hypertension and diabetes were prevalent 
— 221 (72.7%) participants reported 
having hypertension and 86 (28.3%) had 
diabetes. Comorbidities were common — 
183 participants (60.2%) had arthritis and 73 
(24.0%) had depression. Four participants 
had a record of prior heart failure but this 
was not confirmed with objective evidence 
or a formal diagnosis. Cardiovascular 
medications were commonly prescribed 
due to the high rate of hypertension in the 
cohort.
The REFER cohort, although similar in 
age and sex to the derivation dataset,15 
had fewer referrals due to shortness of 
breath and more due to ankle oedema and 
lethargy. Hypertension and diabetes were 
observed in greater frequency in the REFER 
population but a lower proportion of patients 
had chronic obstructive pulmonary disease 
(COPD). Prescribing of diuretics was less 
frequent in the REFER cohort but a higher 
proportion were prescribed angiotensin-
converting enzyme (ACE) inhibitors.
Number of participants with heart failure
The expert panel reviewed the data for 
each participant and determined whether 
or not a heart failure diagnosis was present; 
104 participants had heart failure, which 
represented 34.2% (95% CI = 28.9 to 39.8) 
of the cohort. The objective abnormalities 
found on ECG and echo are shown in 
Table 2.
The characteristics of participants with 
and without heart failure are shown in 
Table 3. Participants with heart failure 
were older and half were male. Presenting 
symptom profile was similar. Proportionately 
more patients with heart failure had a history 
of myocardial infarction (16.4% versus 8.5%) 
but there was no significant difference in 
other comorbidities such as hypertension, 
COPD, and arthritis. Depression was more 
common in the non-heart-failure group. 
Cardiovascular medications were more 
likely to be prescribed in those with heart 
failure than those without heart failure. 
The median NT-proBNP level was 
significantly higher in the heart failure 
group. At the lower 125 pg/ml cut-off, over 
half of patients without heart failure had an 
NT-proBNP above the threshold for referral 
to echocardiography.
Diagnostic accuracy estimates
The diagnostic accuracy of the CDR, 
NT-proBNP level, and their combination is 
shown in Table 4. The clinical information 
(MICE symptoms) of the CDR had a 
sensitivity of 44.2% (95% CI = 34.5 to 54.3), 
but with the addition of the NT-proBNP 
level at the lower cut-offs this improved 
to a sensitivity of 90.4% (95% CI = 83.0 to 
95.3) and specificity 45.5% (95% CI = 38.5 to 
52.7). NT-proBNP level alone with a cut-off 
less than 400 pg/ml had sensitivity 76.9% 
(95% CI = 67.6 to 84.6) and specificity 91.5% 
(95% CI = 86.7 to 95.0). At the lower cut-off 
of 125 pg/ml, sensitivity was 94.2% (95% 
Table 1. Participant characteristics of the REFER study and derivation 
dataseta
 REFER dataset Derivation dataset15 Comparison, 
Characteristic (N = 304) (N = 298) P-valueb
Age, mean, years (SD) 73.9 (8.8) 71.5 (11.5) 0.004
Male 124 (40.8) 122 (40.9) 0.9700
Ethnicity 
 White 214 (70.4) – – 
 Asian/Asian British 56 (18.4) – – 
 Black/black British 16 (5.3) – – 
 Other 18 (5.9) – –
Ankle oedema 248 (81.6) 191 (64.1) <0.0001
Breathlessness 247 (81.3) 283 (95.0) <0.0001
Lethargy 226 (74.3) 184 (62.1) 0.0009
Previous myocardial infarction 34 (11.2) 42 (14.1) 0.2800
Basal crepitations 16 (5.3) 81 (27.2) <0.0001
Hypertension 221 (72.7) 165 (55.4) <0.0001
Diabetes 86 (28.3) 57 (19.1) 0.0083
COPD 17 (5.6) 57 (19.1) <0.0001
Depression 73 (24.0) – –
Arthritis 183 (60.2) – –
Medications 
 ACE inhibitors 98 (32.2) 68 (22.8) 0.0100 
 Beta-blockers 82 (27.0) 68 (22.8) 0.2400 
 ARBs 58 (19.1) – – 
 Diuretics 136 (44.7) 189 (63.4) <0.0001
NT-proBNP median [IQR] 214 [79–494] 381.5 [135–1187] <0.0001
aFigures are N (%) unless stated otherwise. bMeans of the two datasets were compared using a two-sample t-test; 
medians with a Wilcoxon ranked sum test; and proportions with χ2 tests. ACE = angiotensin-converting enzyme. 
ARBs = angiotensin receptor blockers. COPD = chronic obstructive pulmonary disease. IQR = interquartile range. 
SD = standard deviation. NT-proBNP = N-Terminal pro-B type natriuretic peptide levels.
Table 2. Objective abnormalities found on ECG and echo in 
participants with and without heart failure
 Heart failure No heart failure 
Abnormalitya N (%) N (%)
Moderate to severe LVSD — ejection fraction ≤40% 3 (2.9) 0 (0)
Borderline LVSD — ejection fraction 41–50% 9 (8.7)  1 (0.5)
Diastolic dysfunction 15 (14.4) 6 (3.0)
Significant valve disease 47 (45.2) 17 (8.5)
Atrial fibrillation 33 (31.7) 0 (0)
All 104 200
aSome participants had >1 abnormality. ECG = electrocardiogram. LVSD = left ventricular systolic dysfunction.
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CI = 87.9 to 97.9) and specificity 49.0% (95% 
CI = 41.9 to 56.1). 
These performance characteristics 
were mostly lower in magnitude than the 
corresponding values observed in the 
derivation dataset. However, comparison 
of the CIs suggests that the differences 
were not statistically different at the 5% 
level. Figure 2 shows the ROC curves 
of each index test for predicting heart 
failure. Significant differences (P<0.0001) 
were observed between the areas under 
the receiver operating curves (AUROCs) 
shown in Table 4. NT-proBNP had the 
best discriminatory power with AUROC of 
0.91 (95% CI = 0.88 to 0.95) and the clinical 
element (MICE) of the CDR the poorest with 
AUROC 0.54 (95% CI = 0.48 to 0.60).
Table 3. Characteristics of REFER participants with and without heart 
failure
 Heart failure  No heart failure Heart failure versus 
 (N = 104) (N = 200)  no heart failure 
Characteristic N (%) N (%) P-value
Age, years, mean (SD) 77.4 (7.4) 72.1 (9.0) <0.0001
Male 52 (50.0) 72 (36.0) 0.0200
BMI, kg/m2 29.1 (5.7) 31.1 (6.7) 0.0080
Breathlessness 84 (80.8) 163 (81.5) 0.8800
Ankle oedema 87 (83.7) 161 (80.5) 0.5000
Lethargy 72 (69.2) 154 (77.0) 0.1400
Basal crepitations 4 (3.9) 12 (6.0) 0.4200
Previous myocardial infarction 17 (16.4) 17 (8.5) 0.0400
Hypertension 79 (76.0) 142 (71.0) 0.3600
Diabetes 29 (27.9)  57 (28.5) 0.9100
Depression 17 (16.4) 56 (28) 0.0200
COPD 7 (6.7) 10 (5) 0.5300
Arthritis 55 (52.9) 128 (64) 0.0600
ACE inhibitors 38 (36.5) 60 (30.0) 0.2500
Beta-blockers 46 (44.2) 36 (18.0) <0.0001
ARBs 19 (18.3) 39 (19.5) 0.8000
Diuretics 61(58.6) 75 (37.5) 0.0004
NT-proBNP (pg/ml) median [IQR] 715.5 [413 to 1559] 126 [60 to 233] <0.0001
NT-proBNP ≥125 pg/ml N (%) 98 (94.2) 102 (51.0) <0.0001
NT-proBNP ≥400 pg/ml N (%) 80 (76.9) 17 (8.5) <0.0001
ACE = angiotensin-converting enzyme. ARBs = angiotensin receptor blockers. BMI = body mass index. 
COPD = chronic obstructive pulmonary disease. IQR = interquartile range. SD = standard deviation. 
NT-proBNP = N-Terminal pro-B type natriuretic peptide levels.
Table 4. Performance characteristics of the clinical decision rule and NT-proBNP
  Sensitivity Specificity PPV NPV 
 AUROC 95% CI 95% CI 95% CI 95% CI
Derivation dataset15 
 CDR (lower cutoffs)a 0.74 (0.70 to 0.79) 90.2 (82.7 to 95.2) 58.2 (50.9 to 65.2) 52.9 (42.6 to 64.8) 91.9 (75.8 to 100) 
 CDR (upper cutoffs)b 0.75 (0.70 to 0.80) 87.3 (79.2 to 93.0) 62.2 (55.5 to 69.1) 54.6 (46.6 to 62.4) 90.4 (84.1 to 94.8)
REFER 
 CDR (MICE variables) 0.54 (0.48 to 0.60) 44.2 (34.5 to 54.3) 64.0 (56.9 to 70.6) 39.0 (30.1 to 48.4) 68.8 (61.6 to 75.4) 
 CDR+NT-proBNP (lower cut-offsa) 0.68 (0.64 to 0.72) 90.4 (83.0 to 95.3) 45.5 (38.5 to 52.7) 46.3 (39.3 to 53.4) 90.1 (82.5 to 95.1) 
 CDR+NT-proBNP (upper cutoffsb) 0.71 (0.66 to 0.76) 78.8 (69.7 to 86.2) 63.5 (56.4 to 70.2) 52.9 (44.7 to 61.0) 85.2 (78.5 to 90.5) 
 NTproBNP≥125pg/ml alone 0.72 (0.67 to 0.76) 94.2 (87.9 to 97.9) 49.0 (41.9 to 56.1) 49.0 (41.9 to 56.1) 94.2 (87.9 to 97.9) 
 NT-proBNP≥400pg/ ml alone 0.84 (0.80 to 0.89) 76.9 (67.6 to 84.6) 91.5 (86.7 to 95.0) 82.5 (73.4 to 89.4) 88.4 (83.2 to 92.4)
aPost-test probability of 20%. bPost-test probability of 30%. AUROC = area under the receiver operating curve. CDR = clinical decision rule. MICE = Male, Infarction, Crepitations, 
Edema. NPV = negative predictive factor. PPV = positive predictive factor. NT-proBNP = N-Terminal pro-B type natriuretic peptide levels.
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Assessing incorporation bias
The performance characteristics for the 
CDR+NT-proBNP or NT-proBNP alone at 
Steps 1 to 3 are shown in Appendix 1. The 
diagnostic accuracy of all tests increased at 
each step, with largest changes observed 
when NT-proBNP was used without the 
clinical element of the CDR. NT-proBNP 
cut-off 400 pg/ml showed a statistically 
significant increase in the detection of cases 
without heart failure from Step 2 to Step 3 
(P<0.05).
DISCUSSION
Summary
The CDR was not clinically helpful in isolation; 
NT-proBNP testing alone performed as 
well as the validated CDR in determining 
which patients presenting with possible 
heart failure symptoms went on to have a 
diagnosis of heart failure. At a NT-proBNP 
threshold of 125 pg/ml, as advised in ESC 
guidance, 94% of patients who went on to 
have heart failure were identified. However, 
at an NT-proBNP threshold of 400 pg/ml, 
the current level recommended by NICE in 
England, only 77% of heart failure patients 
were appropriately referred. More than one 
in five patients in this study would have been 
misdiagnosed.4
Strengths and limitations
This study included patients presenting 
prospectively to their GP. A large proportion 
of health care in England is provided through 
general practice, and testing the CDR in a 
real-life clinical setting where most patients 
are managed allows accurate validation 
of the rule.23 Participants underwent 
thorough phenotyping, including clinical and 
objective assessment. The data were then 
reviewed by a panel of three experienced 
cardiologists, using a staged system to 
allow for assessment of incorporation bias, 
to agree a formal diagnosis so that the 
‘Observed Disease’ was accurate.24 The 
study was slow to recruit and failed to meet 
the initial target of 500 patients. This was 
due to the requirement to recruit within 
the routine 10-minute consultation at a 
time of unparalleled increased workloads 
in English general practice.25 Furthermore, 
when the study was designed, natriuretic 
peptides were not routinely available and 
therefore the provision of natriuretic peptide 
testing and a rapid diagnostic service, via the 
REFER study, might have been attractive 
to GPs. However, shortly after the study 
commenced, natriuretic peptide assays 
became an open-access diagnostic for 
practices in the region.4 Although fewer 
participants were recruited than planned, 
the performance characteristics of the MICE 
rule were estimated with only marginally 
lower precision than designed. These 
findings also represent the largest diagnostic 
accuracy study conducted in patients with 
undifferentiated symptoms presenting to 
primary care with possible heart failure.
The number of participants with heart 
failure due to reduced ejection fraction was 
unexpectedly low in the cohort. This may 
reflect the nature of heart failure presentation 
where those with left ventricular systolic 
dysfunction may be more likely to present 
acutely direct to secondary care, or may 
already be under the care of a cardiologist 
for a known cardiovascular comorbidity 
such as coronary artery disease.26 
The increase in performance across 
the stepped diagnosis suggests that the 
sensitivity of the index tests may have 
been overestimated due to incorporation 
bias. However, evaluation of the results at 
Step 2 (where NT-proBNP was excluded 
from clinical diagnosis) confirms that the 
diagnostic accuracy of the NT-proBNP test 
alone at the lower cut-off is similar to that 
of the CDR+NT-proBNP.
Comparison with existing literature
Heart failure can be a difficult diagnosis to 
make and the idea of a CDR to help primary 
care clinicians with the decision of who to 
refer for objective testing is justifiable.27 The 
role of CDRs as an aid to clinical decision-
making, however, remains controversial. 
There are many examples of CDRs being 
generated and validated with the hope of 
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improving clinical accuracy but performance 
characteristics are often modest at 
best.28–30 Furthermore, remembering the 
components of a CDR and applying it within 
the consultation can be challenging for busy 
generalist clinicians seeing patients with 
undifferentiated illness.31
The reason the CDR performed no better 
than NT-proBNP alone may be due to the 
diagnosis of heart failure in the cohort 
being largely heart failure with preserved 
ejection fraction. This spectrum of patients 
was different from previous studies of heart 
failure where the prevalence of a low ejection 
fraction (<40%) was more common. The 
derivation and initial validation of the CDR 
relied predominantly on epidemiological 
studies, which included heart failure with 
reduced ejection fraction, so may not directly 
apply to the REFER population.14 In addition, 
the way symptoms were recorded may have 
differed: the study that was used to derive 
the CDR was carried out by cardiologists in 
a secondary care clinic, whereas the REFER 
study data were collected by research 
nurses. However, both studies relied on 
referral from primary care. The prevalence 
of atrial fibrillation and valvular disease was 
also very high in the REFER cohort. This 
may reflect a new reality where clinically 
florid cases of heart failure with reduced 
ejection fraction present to acute services, 
while primary care experiences an increase 
in the number of patients with heart failure 
with preserved ejection fraction, and/or 
other cardiovascular comorbidities.32
Implications for research and practice
The threshold for NT-proBNP below which 
heart failure can be reasonably excluded is 
also an area of ongoing research.33 34 Cost 
effectiveness is an important consideration 
at a population level and is being carried 
out using the results of the REFER study. 
For any test, there is always a trade-off 
between sensitivity and specificity,28 and 
guidelines differ in the threshold they 
currently recommend.4,8 A high sensitivity 
ensures fewer cases are missed, but at 
the expense of more patients undergoing 
echocardiography, a test with limited 
availability in many healthcare systems 
including the NHS in England. But accepting 
a test with a sensitivity that is too low could 
result in a diagnosis of heart failure being 
missed. This study shows that, in patients 
suspected of having heart failure, an 
NT-proBNP blood test alone, at a threshold 
of 125 pg/ml, means heart failure is unlikely 
and thus could be used as a ‘rule out’ test 
to reduce the burden on echo services. At 
the higher NT-proBNP threshold of 400 pg/
ml more than one in five cases of heart 
failure may be missed. Guidelines should 
be revised to ensure natriuretic peptide 
cut-off levels are low enough to ensure GPs 
are not falsely reassured that referral for 
echocardiography is not required.
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Appendix. Performance characteristics of the CDR and NT-proBNP at Steps 1 to 3
 Sensitivity Specificity PPV NPV 
 (95% CI) (95% CI) (95% CI) (95% CI)
CDR+NT-proBNP (lower cut-offs) 
 Step 1 78.8 (67.0 to 87.9) 36.6 (30.4 to 43.0) 25.6 (19.8 to 32.2) 86.1 (77.8 to 92.2) 
 Step 2 85.4 (76.3 to 92.0) 40.9 (34.3 to 47.8) 37.4 (30.8 to 44.5) 87.1 (79.0 to 93.0) 
 Step 3 90.4 (83.0 to 95.3) 45.5 (38.5 to 52.7) 46.3 (39.3 to 53.4) 90.1 (82.5 to 95.1)
CDR+NT-proBNP (upper cut-offs) 
 Step 1 60.6 (47.8 to 72.4) 51.7 (45.1 to 58.2) 25.8 (19.1 to 33.4) 82.6 (75.5 to 88.3) 
 Step 2 74.2 (63.8 to 89.2) 58.6 (51.7 to 65.3) 42.6 (34.7 to 50.8) 84.6 (77.7 to 90.0) 
 Step 3 78.8 (69.7 to 86.2) 63.5 (56.4 to 70.2) 52.9 (44.7 to 61.0) 85.2 (78.5 to 90.5)
NT-proBNP >125  
 Step 1 81.8 (70.4 to 90.2) 38.7 (32.4 to 45.2) 27.0 (21.0 to 33.7) 88.5 (80.7 to 93.9) 
 Step 2 84.3 (75.0 to 91.1) 41.9 (35.2 to 48.8) 37.5 (30.8 to 44.6) 86.5 (78.4 to 92.4) 
 Step 3 94.2 (87.9 to 97.9) 49.0 (41.9 to 56.1) 49.0 (41.9 to 56.1) 94.2 (87.9 to 97.9)
NT-proBNP >400 pg/ml 
 Step 1 48.5 (36.0 to 61.1) 72.7 (66.6 to 78.2) 33.0 (23.8 to 43.3) 83.6 (77.8 to 88.3) 
 Step 2 58.4 (47.5 to 68.8) 79.1 (73.0 to 84.3) 53.6 (43.2 to 63.8) 82.1 (76.2 to 87.1) 
 Step 3 76.9 (67.6 to 84.6) 91.5 (86.7 to 95.0) 82.5 (73.4 to 89.4) 88.4 (83.2 to 92.4) 
CDR = clinical decision rule. NPV = negative predictive factor. PPV = positive predictive factor. NT-proBNP = N-Terminal pro-B type natriuretic peptide levels.
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